Amplia Therapeutics Limited INNMF
Set alert
0.06 USD 0.00 +6.48%
At close · Oct 30
0.0575 Day range 0.0575
0.05 52-week range 0.27
- YTD
- -27.22%
- 1 year
- -36.11%
- Open
- 0.0575
- Prev close
- 0.054
- Mkt cap
- 29.52M
- Vol
- 20.00K
- Avg vol
- 20.88K
- EPS
- -0.01
- P/E
- 0.00
More statistics
- Low
- 0.0575
- High
- 0.0575
1M chart
Signals (9)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 2026 | 3 days ago |
| MACD: Buy Signal | Oct 30, 2026 | 3 days ago |
| SMA: Bearish | Oct 16, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 15, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 13, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 13, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 12, 2026 | 3 weeks ago |
| MACD: Buy Signal | Oct 12, 2026 | 3 weeks ago |
| MACD: Sell Signal | Oct 2, 2026 | 1 month ago |
News
- Amplia Therapeutics partners with Lilly on lung cancer combination trial
- Amplia Signs Collaboration Agreement With Lilly, Evaluating Narmafotinib Plus Lilly's Kras G12C Inhibitor, Olomorasib, in Non-small Cell Lung Cancer
- Scientific Paper Detailing Preclinical Studies of Narmafotinib in Pancreatic Cancer Now Online
- Amplia Announces Publication of New FAK Inhibitor Patent Application
- Amplia Announces Appointment of Brett Carter to Board
- Amplia Announces Changes to Board's Leadership Roles
- Following Significant Advances at ASCO, Amplia Therapeutics Provides Letter to Shareholders Highlighting the Potential Opportunities for Combination with KRAS Inhibition in Pancreatic Cancer
- Amplia Therapeutics Launches First Stage of Registration-Enabling Trial of Narmafotinib
- Amplia Therapeutics and Australia New Zealand Gynaecological Oncology Group (Anzgog) Announce Ovarian Cancer Study
- Accent Trial Mature Data Presented at International Conference
Your note
Sign in to keep a note on INNMF — it syncs with the Stock Master app.